HNN3.0
Register
Register
Register

Project cooperationUpdated on 13 January 2026

In vivo CRISPR-mRNA Cas9 for KO in CD34 HSPCs

Co-founder and CEO at Lempo Therapeutics

Binyamina, Israel

About

Building on our foundational work in ex vivo CRISPR-edited bone marrow HSC therapies, we are initiating a transition toward in vivo hematopoietic genome editing. Our goal is to utilize the same high-efficiency gRNA from our clinical-track ex vivo program to target CD34+ HSCs in situ. This in vivo approach aims to circumvent the infrastructure requirements of specialized transplant centers and the physiological burden of myeloablative conditioning, thereby significantly lowering the barrier to treatment with an already preclinically proven therapy for patients with ANCA-associated glomerulonephritis and for cardiovascular diseases.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health

Type

  • Partner seeks Consortium/Coordinator

Organisation

Lempo Therapeutics

Start-up

Binyamina, Israel

Similar opportunities

  • Project cooperation

    Patient-Derived Zebrafish Larvae Xenografts for Drug Efficacy and Stroma-Interaction Studies

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Vadims Parfejevs

    Lead researcher at Department of Pharmaceutical Sciences, University of Latvia

    Riga, Latvia

  • Project cooperation

    Experts for electrophysiology tackle functional aspects in cardiovascular diseases

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Katarina Danko

    researcher at Department of Biophysics and Electrophysiology, Centre of Biosciences, Slovak Academy of Sciences

    Bratislava, Slovakia

  • Project cooperation

    Translational NAMs in pharmacology & toxicology for drug profiling

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Nikolas Dietis

    Assistant Professor of Pharmacology at University of Cyprus

    Nicosia, Cyprus